Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Mankind Pharma Ltd. is currently processing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are located within 1 distinct art unit, which suggests the company's current filings are technically related. The prosecution involves 2 distinct examiners, requiring the applicant to address different perspectives within the same art unit. MADELINE E BRAUN is the busiest examiner for the company, with 1 pending office action.
Because there are 2 pending office actions and the workload is distributed, each examiner is responsible for a pending office action. This structure means the company must manage separate examiner relationships while maintaining a unified strategy for the 1 distinct art unit involved. The presence of the pending office actions indicates active engagement with the patent office in the Biotechnology & Pharmaceuticals sector. Practitioners should be aware that working with different examiners in the same art unit can lead to different outcomes for similar subject matter. Therefore, monitoring the progress of the action under MADELINE E BRAUN is essential for maintaining consistency. The focus on the distinct art unit simplifies the technical scope, but the involvement of multiple examiners adds a layer of administrative complexity to the pending office actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRAUN, MADELINE E | 1 | 68.0% | +25.7% |
| HAVLIN, ROBERT H | 1 | 51.5% | +28.1% |
| MCMILLIAN, KARA RENITA | 1 | 30.7% | +37.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18316644 | STABLE OPHTHALMIC COMPOSITION OF LOTEPREDNOL | HAVLIN, ROBERT H | 42d overdue |
| 18799812 | PROCESSES FOR THE PREPARATION AND PURIFICATION OF GPR119 AGONIST COMPOUNDS AND INTERMEDIATES THEREOF | BRAUN, MADELINE E | — |
| 17620944 | NOVEL APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | MCMILLIAN, KARA RENITA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18316644 | STABLE OPHTHALMIC COMPOSITION OF LOTEPREDNOL | HAVLIN, ROBERT H | 42d overdue |
| 18799812 | PROCESSES FOR THE PREPARATION AND PURIFICATION OF GPR119 AGONIST COMPOUNDS AND INTERMEDIATES THEREOF | BRAUN, MADELINE E | — |
| 17620944 | NOVEL APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | MCMILLIAN, KARA RENITA | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18799812 | PROCESSES FOR THE PREPARATION AND PURIFICATION OF GPR119 AGONIST COMPOUNDS AND INTERMEDIATES THEREOF | BRAUN, MADELINE E | — | §102§103§112Other | Non-Final OA | — | Pending | Aug 09, 2024 |
| 18316644 | STABLE OPHTHALMIC COMPOSITION OF LOTEPREDNOL | HAVLIN, ROBERT H | 1626 | §102§103§112 | Final Rejection | 42d overdue | Pending | May 12, 2023 |
| 17620944 | NOVEL APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | MCMILLIAN, KARA RENITA | 1623 | §103§112 | Non-Final OA | — | Pending | Dec 20, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial